On page 6, line 18, after "5'-GTAGTCAAGGCTGTAATGATCATC" insert --(SEQ ID NO: 7)--.

In the Claims

Please amend Claims 1-4 and 6-9, and add new Claims 12-23; as follows:

1. (Amended) A [monoclonal] recombinant antibody product , [characterized by an exchange of] comprising the V_H domain of the OKT3 antibody, wherein the cysteine [for another polar amino acid] at position H100A [the OKT3 antibody known under this name] of said V_H domain is substituted with a polar amino acid , wherein said position H100A is according to the Kabat numbering system .

2. (Amended) The [monoclonal] recombinant antibody product , characterized in that the polar amino acid is serine.

N.E.

3. (Amended) The [monoclonal] recombinant antibody product according to claim 1[or 2, characterized in that it includes the sequence indicated in figure 2] comprising the amino acid sequence depicted by SEQ ID NO: 2 .

4. (Amended) A method for the production of the [monoclonal] recombinant antibody product according to any one of claims 1 to 3, characterized by the steps of:

a) [obtainment of] obtaining mRNA from freshly subcloned hybridoma cells of OKT3 and transcription into cDNA,

b) [amplification of] amplifying the DNA coding for the variable domains of the light and heavy chains by means of PCR [using suitable primers] ,

c) cloning of the DNA obtained in b) into a vector adapted for site-specific mutagenesis as well as introduction of [the desired mutation using suitable primers,] a mutation in said position H100A of the V_H domain, wherein said position H100A is according to the Kabat numbering system, wherein said

mutation is the substitution of a cysteine with a polar amino acid, and

d) [insertion of] inserting the mutated DNA obtained in c) in an expression vector and expression in a suitable expression system.

5. (Reiterated) The method according to claim 4, wherein the primers used in step b) are Bi5, Bi8, Bi4 and Bi3f.

6. (Amended) The method according to claim 4 [or 5], wherein the vector used in step c) is pCR-Skript SK(+).

7. (Amended) The method according to [any one of claims 4 to 6] claim 4 , wherein [the primer SK1 5'-GTAGTCAAGGCTGTAATGATCATC is used in step c)] said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7 .

8. (Amended) The method according to [any one of claims 4 to 7] claim 4 , wherein the expression vector used in step d) is pHOG21.

9. (Amended) The method according to [any one of claims 4 to 8] claim 4 , wherein the expression takes place in XL1-Blue E. *coli* cells.

Please the following new claims:

--12. (New) The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).

13. (New) The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

14. (New) The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

15. (New) The method according to claim 5, wherein the expression vector used in step d) is pHOG21.

16. (New) The method according to claim 6, wherein the expression vector used in step d) is pHOG21.

17. (New) The method according to claim 7, wherein the expression vector used in step d) is pHOG21.

18. (New) The method according to claim 4, wherein the expression takes place in XL1-Blue E. *coli* cells.

19. (New) The method according to claim 5, wherein the expression takes place in XL1-Blue E. *coli* cells.

20. (New) The method according to claim 6, wherein the expression takes place in XL1-Blue E. *coli* cells.

21. (New) The method according to claim 7, wherein the expression takes place in XL1-Blue E. *coli* cells.

22. (New) The method according to claim 8, wherein the expression takes place in XL1-Blue E. *coli* cells.

23. (New) A peptide comprising the amino acid sequence depicted by SEQ ID NO: 2.

24. (New) An antibody comprising the peptide according to Claim 23.

25. (New) A single-chain antibody comprising the peptide according to Claim 23.